Beta-synuclein is a promising cerebrospinal fluid and blood biomarker of synaptic damage. Here we analysed its accuracy in the discrimination between sporadic Creutzfeldt-Jakob disease (n = 150) and non-prion rapidly progressive dementias (n = 106). In cerebrospinal fluid, beta-synuclein performed better than protein 14-3-3 (AUC 0.95 vs. 0.89) and, to a lesser extent, than total tau (AUC 0.92). Further, the diagnostic value of plasma beta-synuclein (AUC 0.91) outperformed that of plasma tau (AUC 0.79) and neurofilament light chain protein (AUC 0.65) and was comparable to that of cerebrospinal fluid biomarkers. Beta-synuclein might represent the first highly accurate blood biomarker for the diagnosis of sporadic Creutzfeldt-Jakob disease.

Abu‐Rumeileh, S., Halbgebauer, S., Bentivenga, G.M., Barba, L., Baiardi, S., Mastrangelo, A., et al. (2023). High diagnostic performance of plasma and cerebrospinal fluid beta‐synuclein for sporadic Creutzfeldt–Jakob disease. ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 10(10), 1904-1909 [10.1002/acn3.51873].

High diagnostic performance of plasma and cerebrospinal fluid beta‐synuclein for sporadic Creutzfeldt–Jakob disease

Abu‐Rumeileh, Samir;Bentivenga, Giuseppe Mario;Baiardi, Simone;Mastrangelo, Andrea;Mammana, Angela;Capellari, Sabina;Parchi, Piero
2023

Abstract

Beta-synuclein is a promising cerebrospinal fluid and blood biomarker of synaptic damage. Here we analysed its accuracy in the discrimination between sporadic Creutzfeldt-Jakob disease (n = 150) and non-prion rapidly progressive dementias (n = 106). In cerebrospinal fluid, beta-synuclein performed better than protein 14-3-3 (AUC 0.95 vs. 0.89) and, to a lesser extent, than total tau (AUC 0.92). Further, the diagnostic value of plasma beta-synuclein (AUC 0.91) outperformed that of plasma tau (AUC 0.79) and neurofilament light chain protein (AUC 0.65) and was comparable to that of cerebrospinal fluid biomarkers. Beta-synuclein might represent the first highly accurate blood biomarker for the diagnosis of sporadic Creutzfeldt-Jakob disease.
2023
Abu‐Rumeileh, S., Halbgebauer, S., Bentivenga, G.M., Barba, L., Baiardi, S., Mastrangelo, A., et al. (2023). High diagnostic performance of plasma and cerebrospinal fluid beta‐synuclein for sporadic Creutzfeldt–Jakob disease. ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 10(10), 1904-1909 [10.1002/acn3.51873].
Abu‐Rumeileh, Samir; Halbgebauer, Steffen; Bentivenga, Giuseppe Mario; Barba, Lorenzo; Baiardi, Simone; Mastrangelo, Andrea; Oeckl, Patrick; Steinacke...espandi
File in questo prodotto:
File Dimensione Formato  
2023 Abu-Rumeileh beta-sym in RPDs ACTN.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 401.23 kB
Formato Adobe PDF
401.23 kB Adobe PDF Visualizza/Apri
acn351873-sup-0001-supinfo.pdf

accesso aperto

Tipo: File Supplementare
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 661.66 kB
Formato Adobe PDF
661.66 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/961153
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 3
social impact